Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 14/20 | 0.48 |
| ▸ | ACACB | O00763 | 2/20 | 0.44 |
| ▸ | ACACA | Q13085 | 2/20 | 0.44 |
| ▸ | GRM5 | P41594 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2526541 | 0.97 | GSK3B (0.45) | GSK3BACACBACACAGRM5CYP2C9 | |
| SCHEMBL2488825 | 0.95 | GSK3B (0.46) | GSK3BACACBACACAGRM5CYP2C9 | |
| SCHEMBL2490222 | 0.90 | GSK3B (0.45) | GSK3BGRM5CYP2C9CYP1A2CYP2D6 | |
| SCHEMBL2489453 | 0.88 | GSK3B (0.42) | GSK3BCYP1A2CYP2D6 | |
| SCHEMBL2491589 | 0.88 | GSK3B (0.47) | GSK3BCYP2C9CYP1A2CYP2D6 | |
| SCHEMBL2489805 | 0.86 | GSK3B (0.45) | GSK3BACACBACACAGRM5CYP2C9 | |
| SCHEMBL2489280 | 0.86 | GSK3B (0.48) | GSK3BACACBACACAGRM5CYP1A2 | |
| SCHEMBL2491214 | 0.86 | GSK3B (0.43) | GSK3BCYP2D6 | |
| SCHEMBL2489981 | 0.85 | GSK3B (0.44) | GSK3BCYP2C9CYP1A2CYP2D6 | |
| SCHEMBL2488292 | 0.84 | GSK3B (0.47) | GSK3BCYP1A2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2057141-B1 | PYRIMIDONE COMPOUNDS AS GSK-3 INHIBITORS | PFIZER PROD INC (US) | 2011-10-26 | — | — | EP | disclosed |
| US-20100292205-A1 | Pyrimidone Compounds As GSK-3 Inhibitors | PFIZER INC. (US) | 2010-11-18 | — | — | US | disclosed |
| US-20100292205-A1 | Pyrimidone Compounds As GSK-3 Inhibitors | PFIZER INC. (US) | 2010-11-18 | — | — | US | disclosed |
| WO-2008023239-A1 | PYRIMIDONE COMPOUNDS AS GSK-3 INHIBITORS | PFIZER PRODUCTS INC. (US) | 2008-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292205-A1 | Pyrimidone Compounds As GSK-3 Inhibitors | GSK3B, GSK3A, GSKIP | GSK3B 1/4885ACACB 1317/4885ACACA 1546/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.